EAN 2021 | Oral treatments for MS: S1P modulators

More than 12 treatments, which aim to change the disease course of multiple sclerosis (MS), have been discovered in the last 20 years, including oral treatments; Celia Oreja-Guevara, MD, PhD, University Hospital San Carlos, Madrid, Spain, discusses the benefits of oral treatments for MS and recent developments in the field. This interview took place during the European Academy of Neurology 2021 congress. Oral treatments for moderate disease may be used in first-line, they are generally well-tolerated, the patient is able to avoid injections, and quality of life (QoL) is improved. Recently, 3 new treatments have been added to the S1P1 class of oral MS treatments, which reduce the relapse rate of patients by over 60%, improve progression free survival (PFS) and do not reduce the lymphocyte count to the same extent as other oral treatments. This interview took place during the European Academy of Neurology 2021 congress.